Sabra S Inslicht, PhD
San Francisco VA Medical Center, San Francisco, CA
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sabra S Inslicht, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:49 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT06788522 · The Effects of Orexin Antagonism on Fear Extinction in PTSDVA Office of Research and Development · recruiting · Insomnia, PTSD · principal investigator
- Ph4NCT03642028 · Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic StressVA Office of Research and Development · completed · Sleep Initiation and Maintenance Disorders, Stress Disorders, Posttraumatic · principal investigator
- Ph4NCT00674570 · Veteran Stress and Learning StudyVA Office of Research and Development · completed · Stress Disorders, Posttraumatic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- The Effects of Orexin Antagonism on Fear Extinction in PTSDI01CX002734 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI SABRA INSLICHT · fiscal years 2025Named on NCT06788522
- Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance inPosttraumatic StressI01CX001814 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI SABRA INSLICHT · fiscal years 2019 to 2026Named on NCT03642028
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.